The first cohort will employ an accelerated design to evaluate the first 4 dose levels in single patients. There will be a staggered enrollment with a minimum 1 -week delay between each patient in cohort 1. If any drug-related ≥ Grade 2 (other than Grade 2 injection site reaction with pain) event occurs during the first cycle of treatment, the study will revert to 3+3 design starting at that dose level. Subsequent cohorts in the dose escalation phase will enroll patien ts following the standard 3+3 design. Three patients will be enrolled in each subsequent dose cohort and enrolled with a (minimum) 1 -week staggered delay (i.e. Patient 2 to be dosed ≥1-week after Patient 1 received the first dose, and Patient 3 to be dosed ≥ 1-week after Patient 2 received the first dose). In the 3 -patient cohorts (i.e. 3 patients treated at the same dose), if 1 out of 3 patients experience a DLT during the first two treatment cycles, the dose cohort will be expanded up to 6 patients. If ≥2 out of 6 patients experience DLTs, the MTD has been exceeded, and dose escalation will cease. Up to 3 additional patients will be enrolled at the next lowest dose if only 3 patient s were treated at that dose level, to confirm safety of that dose. If a DLT is observed already with the first patient in Cohort 1, the Safety Review Heat Biologics Protocol No. HS130 -001 A Phase I Study of HS -130 in combination with HS-110 in patients with solid tumors HS130- 001 33 of 60 Version 2.0 - 11 Feb 2020 Confidential - Entire Page Committee ( Section 8.1.2.8.1 ) may suggest and approve a dose de -escalation cohort with at least 50 % reduction of HS -110 and HS -130 (dose level -1). Once all patients in a cohort have completed the first two cycles of dosing and received at least 2 doses of HS-130/HS -110, the safety and tolerability of the combination treatment administered will be reviewed by the safety review committee (SRC). If 0 out of 3 patients or 1 out of 6 patients experience a DLT, then the SRC may recommend enrollment at the next higher dose level. Any patient who does not receive two doses of the study treatment during the DLT window of observation (first 2 cycles /4 weeks ), for reasons other than study drug-related toxicity and did not experience a DLT will not be taken into account in the a ssessment of the overall DLT rate for the particular dose level cohort and will be replaced. 6.1.2 Dose -Limiting Toxicity Adverse events will be assessed per CTCAE version 5. Any toxicity that is at least possibly related to the study drug may be considered as a DLT, which is defined as non -acceptable (as defined below) treatment related toxicity (i.e., not attributable to the active disease, disease -related processes under investigation or intercurrent illness) observed during the first 4 weeks (or Cycle 1 and Cycle 2) of study treatment. Ongoing safety events beyond Cycle 2 will be reviewed across all cohorts during the study to help inform dose escalation decisions. Note, that all patients who enrolled in the study will b e included in assessme nt of DLT . DLT is defined as non -acceptable toxicity which includes: 1. Hematological toxicities ≥ Grade 3. 2. Non -hematological toxicity ≥ Grade 3. 3. Autoimmunity ≥ Grade 3 4. Any other toxicity (greater than at baseline), considered clinically significant and/or unacceptable, and that does not respond to supportive care and results in a disruption of the dosing schedule of more than 14 days. DLT excludes: 1.